Search

Your search keyword '"Tobon, Katherine"' showing total 21 results
Start Over Author "Tobon, Katherine"
21 results on '"Tobon, Katherine"'

4. Outcomes by Best Response With Hypomethylating Agent Plus Venetoclax in Adults with Previously Untreated Acute Myeloid Leukemia

Author

Jain, Akriti G, primary, Volpe, Virginia O, additional, Wang, Chen, additional, Ball, Somedeb, additional, Tobon, Katherine, additional, Chan, Onyee, additional, Padron, Eric, additional, Kuykendall, Andrew, additional, Lancet, Jeffrey E, additional, Komrokji, Rami, additional, Sallman, David A, additional, and Sweet, Kendra, additional

Published
2024
Full Text
View/download PDF

8. Poster: AML-518 Gemtuzumab Ozogamicin in Patients With Newly Diagnosed Acute Myeloid Leukemia – Day 1 vs Day 1, 4 and 7 Regimen

Author

Jain, Akriti, primary, Wang, Chen, additional, Ball, Somedeb, additional, Aguirre, Luis, additional, Schwabkey, Zaker, additional, Tobon, Katherine, additional, Kuykendall, Andrew, additional, Chan, Onyee, additional, Padron, Eric, additional, Lancet, Jeffrey, additional, Komrokji, Rami, additional, Sweet, Kendra, additional, and Sallman, David, additional

Published
2022
Full Text
View/download PDF

10. Leukoencephalopathy During Daratumumab-Based Therapy: A Case Series of Two Patients with Multiple Myeloma

Author

Kareem,Syeda Saba, Viswanathan,Neena, Sahebjam,Solmaz, Tran,Nam D, Gatewood,Tyra, Tobon,Katherine, Baz,Rachid, Piña,Yolanda, Shain,Kenneth H, Mokhtari,Sepideh, Kareem,Syeda Saba, Viswanathan,Neena, Sahebjam,Solmaz, Tran,Nam D, Gatewood,Tyra, Tobon,Katherine, Baz,Rachid, Piña,Yolanda, Shain,Kenneth H, and Mokhtari,Sepideh

Abstract

Syeda Saba Kareem,1 Neena Viswanathan,2 Solmaz Sahebjam,2 Nam D Tran,2 Tyra Gatewood,2 Katherine Tobon,1 Rachid Baz,1 Yolanda Piña,2 Kenneth H Shain,1,3 Sepideh Mokhtari2 1Malignant Hematology Department, Moffitt Cancer Center, Tampa, FL, USA; 2Neuro-Oncology Department, Moffitt Cancer Center, Tampa, FL, USA; 3Tumor Biology Department, Moffitt Cancer Center, Tampa, FL, USACorrespondence: Syeda Saba Kareem, Malignant Hematology Department, Moffitt Cancer Center, 12902 USF Magnolia Drive, Tampa, FL, 33612, Tel +850-321-4383, Fax +813-449-8246, Email syedasaba.kareem@moffitt.orgAbstract: Leukoencephalopathy in the setting of multiple myeloma (MM) is a rare demyelinating condition, with few reported cases in literature. Daratumumab is a CD38 targeted monoclonal antibody that has been widely used for the management of MM. In the absence of central nervous system (CNS) disease, many medication-induced leukoencephalopathy cases reported with MM, including daratumumab-induced, are associated with progressive multifocal leukoencephalopathy (PML) and John Cunningham (JC) virus. Currently, there are no reported cases of daratumumab-induced leukoencephalopathy among patients without CNS involvement or PML. We discuss 2 patients who developed leukoencephalopathy while receiving daratumumab-based therapy without evidence of PML or CNS disease. Both patients had baseline MRIs without significant white matter changes before daratumumab-based therapy. Patients began experiencing neurological deficits about 6 to 8 months after daratumumab-based therapy initiation. One patient passed away before being assessed for improvement of symptoms with daratumumab cessation. The second patient had some stabilization of symptoms after cessation; however, the leukoencephalopathy remained irreversible. As the class of anti-CD38 monoclonal antibodies expands in MM therapy, we highlight a potential treatment complication and the importance of detecting leukoencephalopathy early among patients recei

Published
2022

13. A Retrospective Study on Outcomes of Secondary CNS Lymphoma: Pattern of Relapse, Prognostic Factors, and Role of Consolidation Therapy

Author

Saha, Aditi, Whiting, Junmin, Ammad-ud-din, Mohammad, Powell, Cole, Flores, Kristen, Sanjay, Felix, Sarfraz, Humaira, Jhaveri, Khushali, Jaglal, Michael V., Tobon, Katherine, Saeed, Hayder, Bello, Celeste M., Shah, Bijal D., Isenalumhe, Leidy Lismeris, Pinilla-Ibarz, Javier, Sokol, Lubomir, Chavez, Julio C, and Dong, Ning

Published
2023
Full Text
View/download PDF

17. Safety and financial analysis of outpatient dose-adjusted EPOCH for B-cell lymphoma at a tertiary comprehensive cancer center.

Author

Li, Wenhui, Richter, Katherine A, Tobon, Katherine A, McCarthy, Kevin T, and Kubal, Timothy E

Subjects
ETOPOSIDE, OUTPATIENT medical care, SPECIALTY hospitals, ACQUISITION of data methodology, FEBRILE neutropenia, DOXORUBICIN, B cell lymphoma, ANTINEOPLASTIC agents, RETROSPECTIVE studies, TERTIARY care, CANCER treatment, CANCER patients, MEDICAL care use, DRUG infusion pumps, CYCLOPHOSPHAMIDE, COST effectiveness, MEDICAL records, HOSPITAL care, DESCRIPTIVE statistics, PREDNISONE, VINCRISTINE, ECONOMICS
Abstract

Introduction: Dose-adjusted (DA-) EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) is a front-line treatment option for aggressive B-cell lymphomas. Due to regimen complexity, inpatient administration of DA-EPOCH has been historically required. Moffitt Cancer Center (MCC) developed an Inpatient/Outpatient (IPOP) program to facilitate administration of complicated regimens in the outpatient setting. We hypothesized that outpatient administration of DA-EPOCH at a comprehensive cancer center is both safe and cost-effective. Methods: We conducted a single-center, retrospective chart review including B-cell lymphoma patients who were 18 years or older and who had received DA-EPOCH at MCC from April 26, 2017 through August 10, 2019. The primary endpoint was hospital admissions during outpatient chemotherapy administration. Additional safety endpoints included hospitalizations between cycles, infectious complications, extravasations, drug spills, pump-malfunctions, and drug-related adverse events. Financial analysis included drug cost, resource utilization, and impact of hospital bed backfill. Results: 56 patients received 219 cycles of DA-EPOCH with 193 cycles administered outpatient. Zero patients required hospitalization during outpatient administration of DA-EPOCH, resulting in 965 saved hospital days. 23 patients (41%) were hospitalized between cycles, most commonly due to neutropenic fever (52%). No extravasations were documented throughout the study period. There were few incidences of drug spills or pump malfunctions. Based on current regimen utilization, the annual transition of 84 cycles of DA-EPOCH to the outpatient setting has a positive impact on margin of $1,444,548. Conclusions: Routine outpatient administration of DA-EPOCH is both safe and feasible with a positive annual impact on margin of $1,444,548 at a comprehensive cancer center. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

18. Comparison of Overall Responses after Standard Induction with High Dose Daunorubicin Versus Standard Dose Daunorubicin with Gemtuzumab Ozogamicin in Favorable Risk Acute Myeloid Leukemia

Author

Talati, Chetasi, primary, Caddell, Ryan J, additional, Tobon, Katherine, additional, Komrokji, Rami S., additional, Kuykendall, Andrew T, additional, Padron, Eric, additional, Fernandez, Hugo F., additional, List, Alan F., additional, Sallman, David A, additional, Sweet, Kendra L., additional, and Lancet, Jeffrey E., additional

Published
2019
Full Text
View/download PDF

21. Treatment sequencing patterns for relapsed refractory multiple myeloma (RRMM) in the era of new therapies in a single center institution.

Author

Tungesvik, Alexandre, primary, Sudalagunta, Praneeth Reddy, additional, Huang, Jessica, additional, Dimaggio, Elizabeth, additional, De Avila, Gabe, additional, Tandon, Ankita, additional, Nelson, Rebecca, additional, Olson, Laura, additional, Tobon, Katherine, additional, Shain, Kenneth H., additional, and Brayer, Jason B., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results